Inverness Counsel’s AbbVie ABBV Stock Holding History

Inverness Counsel’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$380K	Buy	2,830 +959	+51%	+$138K	0.02%	140
2022 Q2	$287K	Sell	1,871 -106	-5%	-$16.2K	0.02%	144
2022 Q1	$320K	Buy	1,977 +15	+0.8%	+$2.18K	0.01%	146
2021 Q4	$266K	Buy	+1,962	New	+$232K	0.01%	167
2018 Q2	–	Sell	-2,140	Closed	-$203K	–	134
2018 Q1	$203K	Sell	2,140 -30	-1%	-$3.3K	0.01%	138
2017 Q4	$210K	Buy	+2,170	New	+$205K	0.01%	96
2016 Q4	–	Sell	-4,080	Closed	-$257K	–	93
2016 Q3	$257K	Sell	4,080 -223,830	-98%	-$14.5M	0.02%	79
2016 Q2	$14.1M	Sell	227,910 -145,619	-39%	-$8.87M	1.1%	35
2016 Q1	$21.3M	Buy	373,529 +13,430	+4%	+$749K	1.66%	26
2015 Q4	$21.3M	Sell	360,099 -12,625	-3%	-$727K	1.61%	28
2015 Q3	$20.3M	Buy	372,724 +12,423	+3%	+$809K	1.72%	23
2015 Q2	$24.2M	Buy	360,301 +36,703	+11%	+$2.4M	1.76%	22
2015 Q1	$18.9M	Buy	323,598 +316,040	+4,182%	+$19.1M	1.39%	27
2014 Q4	$495K	Sell	7,558 -1,132	-13%	-$71.4K	0.04%	85
2014 Q3	$502K	Buy	8,690 +3,082	+55%	+$171K	0.04%	84
2014 Q2	$317K	Buy	+5,608	New	+$294K	0.02%	98

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Inverness Counsel's ABBV Position: Q3 2022 in Review

Inverness Counsel increased its AbbVie (ABBV) stake by 51% in Q3 2022, buying an estimated $138K and bringing the position to 2,830 shares worth $380K. The position accounts for 0.02% of the portfolio, ranked #140.

Inverness Counsel first reported a position in ABBV in Q2 2014 and has held it in 16 quarters since. The position peaked at $24.2M in Q2 2015. 2,970 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.

Inverness Counsel held 2,830 shares of AbbVie worth $380K as of Q3 2022.
Inverness Counsel bought 959 AbbVie shares in Q3 2022, an estimated $138K.
AbbVie made up 0.02% of Inverness Counsel's portfolio in Q3 2022, its #140 holding.
Inverness Counsel first reported a position in AbbVie in Q2 2014 and has held it in 16 quarters since.
Inverness Counsel's AbbVie position peaked at $24.2M in Q2 2015.
2,970 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.

Based on Inverness Counsel's 13F filing for Q3 2022, filed 26 Oct 2022.